Smoking-related interstitial lung disease
File(s)
Accepted version
Author(s)
Chakrabarti, AM
Jacobs, J
Molyneaux, PL
Devaraj, A
Chua, F
Type
Journal Article
Abstract
Chronic or heavy smoking can lead to different forms of pathologic remodeling in the airways and distal lung. There is an 8% to 19% prevalence of interstitial lung disease (ILD) in chronic smokers who were unaware that they had a lung disorder. Descriptive pathologic and radiologic analyses have enabled a number of clinical diseases to be identified and grouped within a range of smoking-related ILDs. We review the radiology, pathology, and clinical management of pulmonary Langerhans cell histiocytosis, respiratory bronchiolitis-associated ILD, and desquamative interstitial pneumonia. We discuss the difficulties of classification and also where the new entity of airspace enlargement with fibrosis fits into the current grouping. The prognosis for these conditions is variable depending on the intrinsic behavior of each condition. Smoking cessation is the first-line therapy of choice for any smoking-related ILD, whereas treatment with corticosteroids and other agents forms an important, but occasionally futile, intervention.
Date Issued
2016-07
Date Acceptance
2016-07-01
Citation
Clinical Pulmonary Medicine, 2016, 23 (4), pp.151-156
ISSN
1068-0640
Publisher
Lippincott, Williams & Wilkins
Start Page
151
End Page
156
Journal / Book Title
Clinical Pulmonary Medicine
Volume
23
Issue
4
Copyright Statement
© 2016 Wolters Kluwer Health, Inc. All rights reserved This is a non-final version of an article published in final form in Clinical Pulmonary Medicine (http://dx.doi.org/10.1097/CPM.0000000000000150)
Subjects
Respiratory System
Publication Status
Published
Date Publish Online
2016-07